


Capillary Electrophoresis - Mass Spectrometry

Transforming Biotherapeutics Quality Assessment

James Xia, Ph.D.



EMAS-II



7100 CE

6545XT Q-TOF

July 12, 2018

Common IEF-based Charge Variants Analysis Techniques

Isoelectric Focusing Gel






Figure courtesy of Antibody Solutions.
www.antibody.com

Imaged Capillary Isoelectric Focusing




<http://www.bioprocessintl.com/analytical/product-characterization/imaged-capillary-isoelectric-focusing-for-charge-variant-analysis-of-biopharmaceuticals-323451/>

Bevacizumab cIEF-MS and icIEF-UV results



Fully automated cIEF-MS for IgG charge variants analysis



Capillary Isoelectric Focusing-Mass Spectrometry Method for the Separation and Online Characterization of Intact Monoclonal Antibody Charge Variants


Jun Dai,^{*,†} Jared Lamp,[‡] Qiangwei Xia,[†] and Yingru Zhang[†]

[†]Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States


[‡]CMP Scientific, Corporation, 760 Parkside Avenue, Suite 211, Brooklyn, New York 11226, United States

Supporting Information


ABSTRACT: We report a new online capillary isoelectric focusing-mass spectrometry (CIEF-MS) method for monoclonal antibody (mAb) charge variant analysis using an electrokinetically pumped sheath-flow nanospray ion source and a time-of-flight MS with pressure-assisted chemical mobilization. To develop a successful, reliable CIEF-MS method for mAb, we have selected and optimized many critical, interrelating reagents and parameters that include (1) MS-friendly anolyte and catholyte; (2) a glycerol enhanced sample mixture that reduced non-CIEF electrophoretic mobility and band broadening; (3) ampholyte selected for balancing resolution and MS sensitivity; (4) sheath liquid composition optimized for efficient focusing, mobilization, and electrospray ionization; (5) judiciously selected CIEF running parameters including injection amount, field strength, and applied pressure. The fundamental premise of CIEF was well maintained as verified by the linear correlation ($R^2 = 0.99$) between pI values and migration time using a mixture of pI markers. In addition, the charge variant profiles of trastuzumab, bevacizumab, infliximab, and cetuximab, obtained using this CIEF-MS method, were corroborated by imaged CIEF-UV (iCIEF-UV) analyses. The relative standard deviations (RSD) of absolute migration time of pI markers were all less than 5% ($n = 4$). Triplicate analyses of bevacizumab showed RSD less than 1% for relative migration time to an internal standard and RSD of 7% for absolute MS peak area. Moreover, the antibody charge variants were characterized using the online intact MS data. To the best of our knowledge, this is the first time that direct online MS detection and characterization were achieved for mAb charge variants resolved by CIEF as indicated by a well-established linear pH gradient and correlated CIEF-UV charge variant profiles.



Electrokinetically pumped sheath-flow nanospray



CMP Scientific EMASS-II CE-MS Technology





CMP EMASS-II ion source for Agilent mass specs




Agilent 7100 - CMP EMASS-II – Agilent 6545 Q-TOF



EMASS-II CE-MS Technology On Agilent MS




Schematic flow of the fully automated cIEF-MS method




Solution	Components
Sheath liquid	20% acetic acid, 20% acetonitrile
Catholyte	0.2 N NH_4OH , 15% glycerol
Sample solution	1-1.5% Pharmalyte®, 15% glycerol
Anolyte	1% formic acid, 15% glycerol


MS spectra of proteins in the presence of ampholyte





Sheath solution optimization for cIEF-MS





Sheath solution optimization for IgG cIEF-MS analysis




Glycerol is important for focusing and optimal resolution



cIEF-MS of pI markers under standard conditions




cIEF-MS on a 100 cm PS1 capillary




cIEF-MS and icIEF analysis of mAb molecules




Bevacizumab cIEF-MS and icIEF-UV results





Trastuzumab cIEF-MS analysis in comparison with icIEF-UV



Infliximab cIEF-MS analysis in comparison with icIEF-UV




Cetuximab cIEF-MS analysis in comparison with icIEF-UV




cIEF-MS analysis of Daratumumab



cIEF-MS analysis of Daratumumab



cIEF-MS analysis of Daratumumab





cIEF-MS analysis of Daratumumab





IgG Subunits Analysis (CZE-MS): Low Carryover


Reduced IdeS digest of NISTmAb



IgG Intact Mass Analysis: On-line Desalting

Intact mass analysis of Pembrolizumab









Immunoaffinity Capture - CE-MS: Preclinical ADME



Which Fc-fusion constructs are more stable *in vivo*?



Mice dosed with Fc-protein WT

1h 8h 24h 48h 72h 96h




**Post-dosing
Serum**

Immunoaffinity capture



CE-MS



Mice dosed with Fc-protein RG mutation

1h 8h 24h 48h 72h 96h





Immunoaffinity capture




CE-MS

CE-MS results of Fc-fusion WT PK samples




CE-MS results of Fc-fusion protein WT PK samples




33

Identified species in Fc-protein WT PK samples




Identified species in Fc-protein RG mutation samples




35

Fc-protein PK profiles plotted using peak abundance

A




B



Peptide Mapping of ADCs

EMASS-II CE-MS Technology Enhances Peptide Mapping



ask the expert




Professor Robert J. Linhardt

ASK THE EXPERT

DEVELOPMENTS IN CAPILLARY ELECTROPHORESIS MASS SPECTROMETRY (CE-MS) by Rachel Muenz


Professor Robert J. Linhardt received his PhD in chemistry from Johns Hopkins University in 1979 and did postdoctoral studies at MIT. He is the Anne and John Broadbent Jr. '59 Senior Constellation Chair in Biocatalysis and Metabolic Engineering at Rensselaer Polytechnic Institute. His research focuses on glycoscience and he is an expert on glycosaminoglycans. He has received multiple honors, including the ACS Isbell, Hudson, and Wolfrom Awards; the Volwiler Research Achievement Award; and the Scientific American 10. Dr. Linhardt is a fellow of the National Academy of Inventors, holds over 50 patents, and has authored over 800 research articles.



Q: Why is the interface so important?

A: Before this interface, it was very difficult to interface capillary electrophoresis and mass spectrometry. We think capillary electrophoresis is an excellent way to perform separations, but until we had a CE-MS interface that worked, we were unable to do these types of experiments.

Summary: Agilent-CMP CE-MS Workflow



For Research Use Only, not for Use in Clinical Procedures.

© 2018 CMP Scientific Corp. All rights reserved.

Discussion Period



Dr. James Xia

CEO

CMP Scientific Corporation

760 Parkside Ave., Brooklyn, NY 11226

Email: james.xia@cmpscientific.com



Wayne Heacock

Business Development Manager,

Biopharmaceutical

Agilent Technologies, Inc.

Email: wayne_heacock@agilent.com